Taurine supplemented cell culture medium and methods of use

Patent metadata

Field	Value
Publication number	US-10927342-B2
Application number	US-202016742670-A
Country	US
Kind code	B2
Filing date	Jan 14, 2020
Priority date	Aug 4, 2015
Publication date	Feb 23, 2021
Grant date	Feb 23, 2021

Abstract

The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to the serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.

First claim

What is claimed is:

1. A method for cultivating a eukaryotic cell expressing aflibercept, comprising:
(a) providing a base cell culture medium supplemented with about 0.1 mM to about 10 mM L-taurine;
(b) propagating or maintaining the eukaryotic cell in said base cell culture medium to form a cell culture; and
(c) producing aflibercept from the cell culture;
wherein supplementing the base cell culture medium with L-taurine increases the titer of aflibercept by at least 3% when compared to the titer of aflibercept from cells propagated or maintained in a cell culture medium containing less than 0.1 mM L-taurine.

2. The method of claim 1 , wherein the base cell medium is chemically defined.

3. The method of claim 2 , wherein the base cell medium is serum and hydrolysate free.

4. The method of claim 1 , wherein the base cell medium is supplemented with ornithine, putrescine or a combination thereof at (b).

5. The method of claim 1 , further comprising a growth phase prior to step (b), wherein the growth phase comprises propagating or maintaining the eukaryotic cells in a base cell culture medium that is not supplemented with L-taurine.

6. The method of claim 1 , further comprising a growth phase prior to step (b), wherein the growth phase comprises propagating or maintaining the eukaryotic cells in a base cell culture medium that is supplemented with about 0.1 mM to about 10 mM L-taurine.

7. The method of claim 1 , wherein the taurine of (b) is provided at least once, at least twice, at least 3 times, at least 4 times, or at least 5 times during step (b).

8. The method of claim 1 , wherein the taurine of (b) is provided on each day.

9. The method of claim 1 , wherein the base cell culture medium comprises a mixture of amino acids selected from the group consisting of arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, glycine, proline, alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan.

10. The method of claim 1 , wherein the base cell culture medium comprises one or more fatty acids.

11. The method of claim 10 , wherein the one or more fatty acids are selected from the group consisting of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, and octanoic acid.

12. The method of claim 1 , wherein the base cell culture medium comprises vitamins and cofactors selected from the group consisting of biotin, D-calcium pantothenate, choline chloride, folic acid, myo-inositol, nicotinamide, pyridoxine HCl, riboflavin, thiamine HCl and vitamin B12.

13. The method of claim 1 , wherein the base cell culture medium comprises a mixture of nucleosides.

14. The method of claim 13 , wherein the mixture of nucleosides comprises one or more of adenosine, guanosine, cytidine, uridine, thymidine, and hypoxanthine.

15. The method of claim 1 , wherein the base cell culture medium comprises one or more divalent cations.

16. The method of claim 15 , wherein the one or more divalent cations comprise Ca2+, Mg2+, or both.

17. The method of claim 1 , wherein the eukaryotic cell is selected from the group consisting of a mammalian cell, an avian cell, an insect cell, and a yeast cell.

18. The method of claim 17 , wherein the mammalian cell is selected from the group consisting of a CHO cell, a COS cell, a retinal cell, a Vero cell, a CV-1 cell, a kidney cell, a HeLa cell, a HepG2 cell, a WI38 cell, a MRC 5 cell, a Colo25 cell, a HB 8065 cell, a HL-60 cell, a lymphocyte cell, a A431 cell, a U937 cell, a 3T3 cell, an L cell, a C127 cell, an SP2/0 cell, an NS-0 cell, an MMT cell, a stem cell, a tumor cell, and a derivative thereof.

19. The method of claim 17 , wherein the mammalian cell is a CHO cell, HEK293 cell, or BHK cell.

20. A method for producing aflibercept comprising the steps of:
(a) introducing a nucleic acid comprising a nucleotide sequence encoding aflibercept into a cell;
(b) isolating the cell expressing the aflibercept;
(c) culturing the isolated cell in a cell culture medium comprising about 0.1 mM to about 10 mM L-taurine, thereby producing a population of cells;
(d) expressing aflibercept from the population of cells, wherein the aflibercept is secreted into the medium; and
(e) harvesting the aflibercept;
wherein the addition of about 0.1 mM to about 10 mM L-taurine to the cell culture medium increases the titer of aflibercept by at least 3% when compared to the titer of aflibercept from cells cultured in a cell culture medium containing less than 0.1 mM L-taurine.

21. The method of claim 20 , wherein the titer of the aflibercept is increased by at least 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, or 20% when compared to cells cultured in a cell culture medium containing less than 0.1 mM L-taurine.

22. The method of claim 20 , wherein the population of cells is capable of at least 8% higher protein yield of aflibercept compared to cells expressing aflibercept in a cell culture medium containing less than 0.1 mM L-taurine.

23. The method of claim 20 , wherein producing aflibercept by culturing the population of cells in a cell culture medium with L-taurine is capable of increasing aflibercept yield by at least 0.1 g/L, at least 0.5 g/L, at least 1 g/L, at least 1.2 g/L, at least 1.4 g/L, at least 1.6 g/L, at least 1.8 g/L, at least 2 g/L, at least 2.2 g/L, at least 2.4 g/L, or at least 2.5 g/L when compared to culturing the population of cells in a similar cell culture medium that contains less than 0.1 mM taurine.

24. The method of claim 20 , wherein the cell is a CHO cell, HEK293 cell or BHK cell.

25. The method of claim 20 , comprising culturing the population of cells in the cell culture medium comprising about 0.1 mM to about 10 mM L-taurine at (c) for at least 6 days.

26. The method of claim 20 , wherein the nucleic acid encoding aflibercept is stably integrated in the cell.

27. The method of claim 20 , wherein the cell culture medium comprising L-taurine is capable of decreasing ammonia accumulation by at least 3%, or at least 8%, when compared to a similar cell culture medium that contains less than 0.1 mM taurine.

28. The method of claim 20 , comprising the step of adding one or more point-of-use additions to the cell culture medium.

Assignees

• Regeneron Pharma
• Regeneran Pharmaceuticals Inc

Inventors

• Johnson Amy S
• Casey Meghan E
• Oshodi Shadia
• Lawrence Shawn

Classifications

• C12N15/85

  for animal cells · CPC title

• C12P21/00

  Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

• C12N2500/90

  Serum-free medium, which may still contain naturally-sourced components · CPC title

• C12N2500/46

  Amines, e.g. putrescine · CPC title

• C12N2510/02

  Cells for production · CPC title